Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Novo

Ozempic maker now wants to keep people from becoming obese in the first place

Novo Nordisk is investing in obesity prevention, the 'real big frontier' of weight loss.

Fortune

Why You Should Go Overweight On Novo Nordisk Stock

Novo Nordisk is already the global kingpin in diabetes treatments, with about 30% of the $50+ billion global diabetes market and around half of the $20 billion insulin therapy market. Now, it is becoming a powerhouse in weight-loss drugs, thanks to its Wegovy drug.

Barchart

Good Luck Paying for Those $10,000 Obesity Drugs Everyone’s Talking About

Ozempic, Wegovy and Mounjaro can cause dramatic weight loss, and could create a market worth $150 billion a year.

Businessweek

From analysis to the latest developments in health,
read the most diverse news in one place.

Revealed: maker of Wegovy ‘skinny jab’ is funding NHS weight-loss services

Critics fear conflict of interest as Novo Nordisk helps medics ‘reduce unnecessary barriers’ to treatment for obesity

The Guardian - UK

Six-month Ozempic shortage mostly over after weight-loss craze drained supply

Novo Nordisk A/S replenished supplies of Ozempic, a treatment for diabetes, after social media-driven enthusiasm over the drug’s use for weight loss led to six months of shortages.

Tribune News Service

Novo Nordisk will cut some U.S. insulin prices by up to 75% starting next year

The Danish drugmaker's move follows a similar announcement by rival Eli Lilly earlier this month. More than 8 million Americans use insulin, according to the American Diabetes Association.

WEKU

Novo Nordisk to slash insulin price by up to 75% in push for affordable diabetes treatments

The brand is the latest to plan dramatic price cuts for the diabetes drug

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

New obesity drug would cost Medicare $27 billion, even with limited uptake

Covering Novo Nordisk A/S’s new obesity drug Wegovy could strain the budget of US government insurance program Medicare, according to a new analysis in the New England Journal of Medicine.

Tribune News Service

Revealed: experts who praised new ‘skinny jab’ received payments from drug maker

Novo Nordisk gave millions to obesity charities and healthcare professionals, including expert who advised Nice

The Guardian - UK

How to see Coachella bands up-close at intimate venues in Southern California

ANAHEIM, Calif. — Music fans may already have their wristbands ready for the 2023 Coachella Valley Music & Arts Festival in Indio in April, but if you’re not into making the trek to the desert or the idea of three long days in the heat no longer sounds appealing, there…

The Orange County Register

Obesity treatments catch drugmakers’ eyes as sales seen soaring

Three years ago, drugmakers and laboratories around the world responded to the pandemic with Covid-19 vaccines. Now that the urgency has faded, they’re collectively turning attention to an older pandemic: obesity.

Tribune News Service

A TikTok trend sold out Ozempic, leaving people with diabetes dizzy, scared

For more than a month, Shane Anthony, a 57-year-old auto mechanic, hasn’t been able to get his diabetes medication.

Tribune News Service

The growing market for weight loss drugs

A new generation of FDA-approved diabetes drugs that can also help patients lose weight has prompted enthusiasm from doctors and a firestorm of demand among patients so strong it's led to shortages.

Axios

Novo Nordisk shot helps teens lose weight, new study finds

Novo Nordisk A/S’s weekly shot that reduces obesity in adults returned promising results in teens, according to a study that adds to a growing wave of potential interventions for the stubborn condition.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

New generation of weight loss medications offer promise — but at a price

Excitement is building about a new generation of drugs that tout the ability to help adults with excess weight shed more pounds than older drugs on the market.

Los Angeles Times

Led by a surprise No. 1 hit, Steve Lacy redefines the rock star for Gen Z

LOS ANGELES — In September, Steve Lacy sauntered into the glassy upstairs lounge at the Novo in downtown L.A. bearing some remarkable news. The 24-year-old, Compton-raised singer-songwriter, dressed in a flowy trench coat, shoulder-length braids and imposing full-face sunglasses, had just learned that "Bad Habit," his bummed-out yet deliriously horny…

Tribune News Service

Royal Blood remember Foo Fighters’ Taylor Hawkins ahead of Southern California shows

With a new album to play live, English rock band Royal Blood was ready to go when it launched its tour in the United Kingdom earlier this year.

Chronicle Live

Morpeth's Novo restaurant is celeb central as Kieran Trippier and Vicky Pattison lead star diners

Novo restaurant in Morpeth has become a big favourite with celebrities including Kieran and his Newcastle United team mates

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Novo Nordisk Doubles 2025 Sales Target On Strong Wegovy Demand

Novo Nordisk A/S (NYSE: NVO) has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug.

Input

How Twitch's culture of secrecy hurts creators

Devin Nash, CMO of influencer marketing agency Novo Studios, believes Twitch's problems won't be solved anytime soon.

Benzinga

Novo Nordisk Posts Upbeat Q4 Earnings, Expects Obesity Drug Shortages May Soon Be Resolved

Novo Nordisk A/S (NYSE: NVO)

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.